Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Breast Cancer
Interventions: Alloderm RTU, Cortiva 1mm Allograft Dermis, Skin or nipple-sparing mastectomy, Breast Q, Surgery; Other · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 22 Years to 70 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression, Depression During the Menopausal Transition, Menopausal Depression
Interventions: Phase Advanced Intervention (PAI), Phase Delay Intervention (PDI); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: High Risk Hematological Malignancy, Cord Blood Transplant
Interventions: ECT-001-CB (UM171-Expanded Cord Blood Transplant); Biological
Lead sponsor: ExCellThera inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Hematologic Neoplasms
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more

Conditions: Atopic Dermatitis
Interventions: Infrequent versus Frequent Soaking Baths; Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 6 Months to 11 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Cancer
Interventions: SRK-181, anti-PD-(L)1 antibody therapy; Biological
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Fullerton, California • La Jolla, California • Los Angeles, California + 14 more

Conditions: Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
Interventions: Zanubrutinib, Rituximab, Epcoritamab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 30
States / cities: Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more

Conditions: Healthy Volunteer
Interventions: AG-348, Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Upper Extremity Lymphedema
Interventions: QBX258; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Rotator Cuff Tear Surgical Repair
Interventions: Routine post-surgical care plus H-Wave® Device Stimulation (HWDS), Routine post-surgical care; Device · Other
Lead sponsor: Electronic Waveform Lab; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Overland Park, Kansas • Kansas City, Missouri • Lee's Summit, Missouri + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin, Ranolazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anger, Aggression
Interventions: ACT with RAGE-Control; Behavioral
Lead sponsor: Gonzalez-Heydrich, Joseph, M.D.; Individual
Eligibility: 8 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Myeloma
Interventions: Pomalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Ureter Injury
Interventions: Lumitrace, KARL STORZ POWER LED BLUE System; Drug · Device
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Alcohol; Harmful Use
Interventions: In-person sessions: ABCP_P, Video conference sessions: ABCP_T; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hypertension
Interventions: COREG CR, Lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Migraine Disorders
Interventions: Capsaicin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Phoenix, Arizona • Encino, California • Glendale, California + 9 more

Conditions: Morbid Obesity
Interventions: REALIZE™ Swedish Adjustable Gastric Band; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Miami, Florida + 5 more

Conditions: Healthy Subjects
Interventions: HTC-867, Placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: MK-6916, Diltiazem; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Total Knee Replacement Surgery
Interventions: ultrasound guidance alone, ultrasound guidance and needle stimulation, ultrasound guidance and catheter stimulation; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Graft Failure
Interventions: FLT imaging and TK1 blood measurements; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 4 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Search by objective public record fields.

Compare Outcomes Between Two Acellular Dermal Matrices

Sleep and Light Intervention (SALI) for Menopausal Mood Dysfunction

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Epco, Zanu, Ritux for R/R FL or MZL

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

A Phase I Study of AG-348 in Healthy Volunteers

Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)

H-Wave® Device Stimulation for Post-operative Rotator Cuff Repair Surgery

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

Reducing Aggression in Children and Adolescent on an Inpatient Unit

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries

Testing A Couple-based Program for Alcohol Risk Reduction in the National Guard

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

Biomarker Study in Participants With Migraine

Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion

REVEAL Biomarkers of Engraftment After Alternative Donor HSCT